EA200802346A1 - Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с - Google Patents

Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с

Info

Publication number
EA200802346A1
EA200802346A1 EA200802346A EA200802346A EA200802346A1 EA 200802346 A1 EA200802346 A1 EA 200802346A1 EA 200802346 A EA200802346 A EA 200802346A EA 200802346 A EA200802346 A EA 200802346A EA 200802346 A1 EA200802346 A1 EA 200802346A1
Authority
EA
Eurasian Patent Office
Prior art keywords
indobobenzezepinova
helpatitis
cyclopropilcondenated
inhibitors
ns5b protein
Prior art date
Application number
EA200802346A
Other languages
English (en)
Other versions
EA015286B1 (ru
Inventor
Джон А. Бендер
Мин Динг
Роберт Г. Джентлс
Пиасена Хевавасам
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38512732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200802346(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA200802346A1 publication Critical patent/EA200802346A1/ru
Publication of EA015286B1 publication Critical patent/EA015286B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение охватывает соединения формулы (I) также как композиции и способы использования соединений. Соединения имеют активность против инфекционного заболевания гепатита С (HCV) и являются пригодными при лечении указанных инфекций с помощью HCV
EA200802346A 2006-05-17 2007-05-04 Циклопропилконденсированные индолбензазепиновые ингибиторы белка ns5b вируса гепатита с EA015286B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80112506P 2006-05-17 2006-05-17
US80200506P 2006-05-19 2006-05-19
US85208406P 2006-10-16 2006-10-16
US89475707P 2007-03-14 2007-03-14
PCT/US2007/068209 WO2007136982A1 (en) 2006-05-17 2007-05-04 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Publications (2)

Publication Number Publication Date
EA200802346A1 true EA200802346A1 (ru) 2009-06-30
EA015286B1 EA015286B1 (ru) 2011-06-30

Family

ID=38512732

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802346A EA015286B1 (ru) 2006-05-17 2007-05-04 Циклопропилконденсированные индолбензазепиновые ингибиторы белка ns5b вируса гепатита с

Country Status (25)

Country Link
US (1) US7456166B2 (ru)
EP (1) EP2024375B1 (ru)
JP (1) JP5284952B2 (ru)
KR (1) KR101417145B1 (ru)
AR (1) AR061008A1 (ru)
AT (1) ATE501156T1 (ru)
AU (1) AU2007253998B2 (ru)
BR (1) BRPI0711821A2 (ru)
CA (1) CA2651690C (ru)
CY (1) CY1111526T1 (ru)
DE (1) DE602007013036D1 (ru)
DK (1) DK2024375T3 (ru)
EA (1) EA015286B1 (ru)
HK (1) HK1122814A1 (ru)
HR (1) HRP20110194T1 (ru)
IL (1) IL195025A (ru)
MX (1) MX2008014435A (ru)
NO (1) NO341663B1 (ru)
NZ (1) NZ572555A (ru)
PE (1) PE20080070A1 (ru)
PL (1) PL2024375T3 (ru)
SI (1) SI2024375T1 (ru)
TW (1) TWI401244B (ru)
WO (1) WO2007136982A1 (ru)
ZA (1) ZA200809548B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005049622A1 (ja) * 2003-11-19 2007-06-07 日本たばこ産業株式会社 ５−５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2343914T3 (es) * 2006-05-25 2010-08-12 Bristol-Myers Squibb Company Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo.
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
CN101679437B (zh) 2007-03-13 2013-04-17 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2008137126A2 (en) 2007-05-04 2008-11-13 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of hcv infection
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN101918410B (zh) * 2007-11-20 2013-02-27 百时美施贵宝公司 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
JP5623289B2 (ja) 2007-12-19 2014-11-12 ベーリンガーインゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
WO2009080836A2 (en) 2007-12-24 2009-07-02 Tibotec Pharmaceuticals Ltd. Macrocyclic indoles as hepatitis c virus inhibitors
WO2009120733A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
AU2009228337A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8138171B2 (en) * 2008-03-27 2012-03-20 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2010203656A1 (en) 2009-01-07 2011-07-21 Scynexis, Inc. Cyclosporine derivative for use in the treatment of HCV and HIV infection
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US9127010B2 (en) 2010-06-24 2015-09-08 Janssen Sciences Ireland Uc Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
MX2013007698A (es) 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
JP6306002B2 (ja) 2012-07-18 2018-04-04 ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ （４ｂＳ，５ａＲ）−１２−シクロヘキシル−Ｎ−（Ｎ，Ｎ−ジメチルスルファモイル）−３−メトキシ−５ａ−（（１Ｒ，５Ｓ）−３−メチル−３，８−ジアザビシクロ［３．２．１］オクタン−８−カルボニル）−４ｂ，５，５ａ，６−テトラヒドロベンゾ［３，４］シクロプロパ［５，６］アゼピノ［１，２−Ａ］インドール−９−カルボキサミドを製造するための新規な方法および中間体
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US752354A (en) * 1904-02-16 Composition post
US753137A (en) * 1904-02-23 Dust-pan
US756203A (en) * 1903-11-14 1904-04-05 Oliver E Barthel Muffler.
DK1719773T3 (da) 2004-02-24 2009-06-29 Japan Tobacco Inc Kondenserede heterotetracykliske forbindelser og anvendelse deraf som HCV-polymeraseinhibitor
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) * 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1799679B1 (de) 2004-10-13 2008-01-23 Merck Patent GmbH Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs
BRPI0516972A (pt) * 2004-10-26 2008-09-30 Angeletti P Ist Ricerche Bio composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) * 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents

Also Published As

Publication number Publication date
IL195025A0 (en) 2009-08-03
CA2651690C (en) 2014-11-04
BRPI0711821A2 (pt) 2012-01-17
KR101417145B1 (ko) 2014-07-08
HRP20110194T1 (hr) 2011-04-30
EP2024375B1 (en) 2011-03-09
AU2007253998B2 (en) 2012-03-15
ZA200809548B (en) 2009-12-30
US7456166B2 (en) 2008-11-25
DK2024375T3 (da) 2011-06-27
HK1122814A1 (en) 2009-05-29
EA015286B1 (ru) 2011-06-30
AR061008A1 (es) 2008-07-30
TW200804282A (en) 2008-01-16
AU2007253998A1 (en) 2007-11-29
NO341663B1 (no) 2017-12-18
PE20080070A1 (es) 2008-03-10
PL2024375T3 (pl) 2011-07-29
EP2024375A1 (en) 2009-02-18
IL195025A (en) 2013-09-30
JP5284952B2 (ja) 2013-09-11
SI2024375T1 (sl) 2011-10-28
TWI401244B (zh) 2013-07-11
CA2651690A1 (en) 2007-11-29
ATE501156T1 (de) 2011-03-15
DE602007013036D1 (de) 2011-04-21
KR20090008344A (ko) 2009-01-21
US20070270405A1 (en) 2007-11-22
CY1111526T1 (el) 2016-02-10
NZ572555A (en) 2010-11-26
NO20084637L (no) 2008-12-15
JP2009537557A (ja) 2009-10-29
MX2008014435A (es) 2008-11-27
WO2007136982A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
DK1987038T3 (da) HCV NS5B-hæmmere
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA200901241A1 (ru) Соединения для лечения гепатита с
CY1113752T1 (el) Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
NO20090453L (no) Hepatitt C Virusinhibitorer
EA201171152A1 (ru) Ингибиторы вируса гепатита c
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
ATE474827T1 (de) Hcv-replikationshemmer
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
ATE492558T1 (de) Makrocyclische peptide als hepatitis-c-virus- hemmer
EA200900676A1 (ru) Ингибиторы вируса гепатита с
EA201000277A1 (ru) Соединения для лечения гепатита с
ATE492559T1 (de) Makrocyclische peptide als hepatitis-c-virus- hemmer
EA201001273A1 (ru) Ингибиторы вируса гепатита с
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
EA200901101A1 (ru) Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU